Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

Phase 1

Completed

Brief Summary: The phase Ib part of the trial will assess the MTD of AUY922 in combination with Trastuzumab in patients with Trastuzumab-refractory locally advanced or metastatic HER2+. The MTD is defined as the highest drug dosage not causing in the first cycle of treatment (28 days) medically unacceptable dose limiting toxicity (DLT).

The phase II part of the trial will assess any potential effect on efficacy of adding AUY922 to Trastuzumab in patients with Trastuzumab-refractory locally advanced or metastatic HER2+ breast cancer.

Both AUY922 and Trastuzumab will be administered as a weekly IV infusion. Treatment should be continued as long as the patient does not have disease progression and tolerates the treatment. The following reasons are examples of acceptable reasons for discontinuing the study; tumor progression (by RECIST, as assessed by the investigator), unacceptable toxicity, death, or discontinuation from the study for any other reason, such as patient refusal, withdrawn consent, lost to follow-up or investigator decision.

Recruitment & Eligibility

Inclusion Criteria

Female patients with confirmed HER-2 positive , non-operable locally advanced or metastatic breast cancer
All patients must have received at least 1 but no more than 2 prior anti HER2 based regimens including at least 1 regimen containing Trastuzumab.
All patients must have at least one measurable lesion as defined by RECIST criteria.
All patients must have documented progressive disease following the last line of therapy before entering the study
ECOG Performance status ≤ 1

Exclusion Criteria

Patients with known CNS metastasis which are: symptomatic or require treatment for symptom control and/or growing
Prior treatment with any HSP90 or HDAC inhibitor
Impaired cardiac function
Acute or chronic liver or renal disease
Patients who are currently receiving treatment with any medication which has a relative risk of prolonging the QTc interval or inducing Torsades de Pointes and cannot be switched or discontinued to an alternative drug prior to commencing AUY922
Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention
Patients who do not have either an archival tumor sample available or are unwilling to have a fresh tumor sample collected at baseline.

Other protocol-defined inclusion/exclusion criteria may apply

Arm && Interventions

Group	Intervention	Description
AUY922 + Trastuzumab	AUY922	-
AUY922 + Trastuzumab	Trastuzumab	-

Primary Outcome Measures

Name	Time	Method
Overall Response Rate as assessed by RECIST (phase ll)	Every 8 weeks for the first 24 weeks and every 12 weeks thereafter
Maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD) of AUY922 in combination with Trastuzumab (phase lb)	4 weeks

Secondary Outcome Measures

Name	Time	Method
Assess concentration of AUY922 and BJP762 in the blood at different time points (phase lb & ll)	4 weeks
Progression Free Survival (PFS) at the RPTD dose (phase ll only)	every 3 months until 24 months after the last patient has been enrolled
Overall Survival (OS) at the RPTD dose	every 3 months until 24 months after the last patient has been enrolled
Assess frequency, intensity and duration of Adverse Events as a Measure of Safety and Tolerability (phase lb & ll)	average 6 months

Locations (2): Novartis Investigative Site
🇬🇧
Oxford, United Kingdom
Highlands Oncology Group Dept of Highlands Oncology Grp
🇺🇸
Fayetteville, Arkansas, United States